5-Azacitidine (azacitidine) is approved for treatment of myelodysplastic syndromes (MDSs) and mixed MDS/MPN (myeloproliferative neoplasm). 1 Its clinical superiority to the related substance cytarabine 2 and the slow onset of response has been attributed to its DNA hypomethylating effects. Although cytarabine induced S-phase arrest in cell line experiments, azacitidine did not interfere with cell cycle progression. 3 Azacitidine has been shown to induce DNA demethylation in myeloid cell lines and to induce reexpression of genes silenced by aberrant promoter methylation. 4, 5 Other studies show that its mechanisms of action are complex and involve induction of apoptosis, 6 immunomodulation, 7 differentiation of blasts, 4 histone modifications 8 and inhibition of RNA methylation. 9 Sequential samples from patients under treatment show reduced CDKN2B promoter methylation in complete remission and reappearance of methylation before relapse, 10, 11 but this may also reflect replacement of cancer cells with normal hematopoiesis and vice versa. The effect of azacitidine on MDS bone marrow (BM) progenitors in vitro has not been investigated in detail.
We assessed the direct effects of azacitidine on BM progenitors from patients with high-risk MDS eligible for azacitidine treatment according to label and from healthy controls (normal BM ¼ NBM), respectively. The clinical characteristics of the eight patients included in the main experiment, methylation array (Illumina, San Diego, CA, USA) and corresponding western blot analysis, are shown in Supplementary Table 1 . Mononuclear cells (MNCs) were sorted from freshly harvested BM by density gradient technique (Lymphoprep, Axis-Shield, Oslo, Norway). CD34 þ cells were then purified by magnetic bead sorting (Progenitor Cell Isolation kit, Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured in RPMI Glutamax with 10% fetal bovine serum, 10 ng/ml granulocyte colony-stimulating factor (G-CSF), 10 ng/ml interleukin-3 and 24 ng/ml stem cell factor with varying concentrations of azacitidine. DNA was extracted using Gene Elute genomic DNA Letters to the Editor extraction kit (Sigma, St Louis, MO, USA) and bisulfite conversion was carried out using EZ methylation gold kit (Zymo Research, Irvine, CA, USA). First, pyrosequencing was applied to analyze global methylation levels by LINE-1 repetitive elements on DNA.
12 Azacitidine-treated positions showed less methylation than controls in both NBM (1 mM P ¼ 0.001) and MDS (1 mM; P ¼ 0.02). There was no difference between 1 and 2 mM azacitidine (P ¼ 0.21) or incubation for 24 or 48 h (P ¼ 0.19). Consequently, 1 mM and 24 h was chosen for the subsequent Illumina Bead Chip array (Illumina) to minimize unwanted effects from longer culture conditions per se.
Eight high-risk MDS patients and four normal controls were assessed by the Illumina Infinium HumanMethylation 450K Beadchip array (Illumina) for their genome-wide DNA methylation pattern, with and without in vitro exposure to azacitidine. There were 32 155 significantly differentially methylated sites in untreated MDS vs untreated NBM. The majority (89%) of sites were more methylated in MDS than in NBM (Figure 1a) . Indeed, increased DNA methylation has been previously demonstrated in MDS 13 but the Illumina assay used in this study provides more information about genome-wide patterns. Azacitidine at 1 mM for 24 h induced a marked genome-wide hypomethylation in CD34 þ MDS progenitors and induced significant alterations at 15 531 examined sites, whereof 96% were less methylated after azacitidine treatment (15 448/15 531; Figure 1c) . The global LINE-1 method showed less prominent changes, which supports the value of advanced next-generation sequencing techniques. Importantly, the demethylating effect was not promoter specific but included to an equal degree non-promoter CpG-sites, and CpG-islands, shores and shelves were equally affected. Interestingly, only 1% (239/32 155, intersection in Venn diagram Figure 1a ) of the sites that were aberrantly methylated in untreated MDS vs NBM were altered by azacitidine treatment. In these 239 sites, azacitidine restored the methylation level toward that of NBM. Unexpectedly, only 3% (8/239) corresponded to a gene promoter (nine genes; FADD, PBX4, KRTCAP3, NRBP1, CHST12, MALAT1, GEMIN7, CPS1, LANCL1), which suggests that other effects than re-expression of genes silenced by aberrant DNA hypermethylation are activated by azacitidine. Azacitidine also induced demethylation in NBM progenitors but the difference did not reach statistical significance (Figure 1d ), which indicates differential effects on normal and MDS progenitors.
Although azacitidine has an anti-proliferative effect on myeloid cell lines 6 and despite the marked demethylating effect in the CD34 þ MDS cultures, there was a minimal effect on cell proliferation in MNC suspension cultures. Incubation of MNC with up to 2 mM for 24 and 48 h had no significant effect on cell count or viability in either NBM (N ¼ 9) or MDS (N ¼ 10; Figures 2a  and b) . Even in cultures incubated with 5 mM (N ¼ 3 MDS and 7 NBM) or for 72 h (N ¼ 1 MDS and 6 NBM) the effect on cell growth was limited or absent (data not shown).
Similar effects were observed in colony cultures (MethoCult) plated with CD34 þ cells after 24 h of incubation with azacitidine (0-5 mM) and counted on day 14. Doses up to 0.5 mM had no inhibitory effect on either erythroid or myeloid colony growth (Figures 2c and d) . By contrast, lower doses induced a moderate increase of in particular erythroid colonies. The number of colonies was increased by 470% in azacitidine-treated positions in 5/8 and 5/12 of the NBM and MDS experiments, respectively. These findings corroborate previous clinical observations from our group, that azacitidine maintenance in patients with complete remission after chemotherapy causes neutropenia and thrombocytopenia but almost no anemia between cycles. 10 There was, however, a large variation between cultures and the differences were not statistically significant (NBM: P ¼ 1.0, MDS: P ¼ 0.6).
The effect of azacitidine on histone modifications has been sparsely investigated. One study showed an increase in H3K27me3 and H3K9me3 after 4 days of incubation of HEK293 cells with azacitidine. 8 Our initial hypothesis was that H3K9ac and H3K27ac (markers of active chromatin) would increase after azacitidine treatment, because of chromatin activation within previously silenced promoter regions. By contrast, we showed a decrease of histone acetylation after azacitidine treatment (Figure 2e ). H3K9ac decreased in eight of eight examined patients (average decrease 48%, Po0.05) and H3K27ac decreased in five of six examined patients (average 35%, P ¼ 0.15) as assessed by western blot analysis. This pattern was not observed in normal CD34 þ cells, which remained largely unaffected or showed slightly increased acetylation. H3 and H4 were run as loading controls and showed stable and similar loading, which ensures that the effects did not reflect alterations in global H3/H4 ratio. We hypothesize that the observed pattern may be due to interplay between DNA methylation and chromatin structure; if gene silencing by DNA methylation is lost, histone modifications will keep chromatin repressed. As support for this, global DNA hypomethylation was recently linked to repressive chromatin and gene silencing.
14 Upregulation of HDAC genes by demethylation after azacitidine treatment, and hence, a global reduction of histone acetylation could be one reason for resistance or incomplete clinical response to azacitidine. A previous study showed that expression of HDAC1 and HDAC3 increases after treatment of MDS cells with azacitidine. 15 Interestingly, we found that the gene encoding for the histone deacetylase enzyme HDAC4 became hypomethylated in MDS progenitor cells upon azacitidine treatment. Thus, it is possible that increased HDAC4 levels are contributing to the observed reduction of H3K27ac and H3K9ac.
We conclude that azacitidine induces profound and global DNA hypomethylation in MDS CD34 þ progenitors, which is not restricted to promoter areas or to aberrantly hypermethylated regions in MDS. Despite this, azacitidine has limited antiproliferative effects on normal and MDS progenitors and possibly, in low doses, a moderately enhancing effect on erythroid proliferation. The limited effects of azacitidine on normal progenitors may support the use of azacitidine as maintenance after stem cell transplantation. Finally, we demonstrate a clear decrease in markers of active chromatin, suggesting that the mechanisms of azacitidine are more complex than re-expression of silenced genes and activation of chromatin. This may provide an explanation as to why certain patients do not respond to treatment.
